No Data
No Data
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Express News | Relmada Therapeutics Inc - Phase 2a Proof-of-Concept Study Expected to Begin in H1 2025
Express News | Relmada Therapeutics Initiates Phase 1 Dosing With Rel-P11 for Metabolic Disease
Relmada Therapeutics Initiates Phase 1 Dosing With REL-P11 for Metabolic Disease
Relmada Therapeutics: Strong Buy on Promising Pipeline and Financial Stability
Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript Summary
No Data
No Data